---
permalink: /
title: ""
excerpt: ""
author_profile: true
redirect_from: 
  - /about/
  - /about.html
---

{% if site.google_scholar_stats_use_cdn %}
{% assign gsDataBaseUrl = "https://cdn.jsdelivr.net/gh/" | append: site.repository | append: "@" %}
{% else %}
{% assign gsDataBaseUrl = "https://raw.githubusercontent.com/" | append: site.repository | append: "/" %}
{% endif %}
{% assign url = gsDataBaseUrl | append: "google-scholar-stats/gs_data_shieldsio.json" %}

<span class='anchor' id='ç®€ä»‹'></span>

åˆ˜æ—­æ˜‡ï¼Œç”·ï¼Œ1994å¹´1æœˆç”Ÿï¼Œæ¹–åŒ—åŒ»è¯å­¦é™¢åŒ»å­¦å½±åƒä¸æ ¸åŒ»å­¦ç¡•å£«ï¼Œå¤ªå’ŒåŒ»é™¢æ ¸åŒ»å­¦ç§‘ä¸»æ²»åŒ»å¸ˆ/åŠ©æ•™ã€‚ä¸»è¦ä»äº‹æ ¸åŒ»å­¦SPECT/CTã€PET/CTåˆ†å­åŠŸèƒ½å½±åƒè¯Šæ–­ï¼›è‚¿ç˜¤åˆ†å­é¶å‘åŠŸèƒ½å½±åƒè¯Šæ–­å’Œæ²»ç–—ç ”ç©¶ç­‰ã€‚å‚ä¸å›½å®¶è‡ªç„¶ç§‘å­¦åŸºé‡‘1é¡¹ï¼Œä¸»æŒçœçº§è¯¾é¢˜1é¡¹ã€‚æ›¾è£è·â€œåå °å¸‚ä¼˜ç§€å…±é’å›¢å¹²éƒ¨â€ã€â€œæ¹–åŒ—åŒ»è¯å­¦é™¢ä¼˜ç§€å…±äº§å…šå‘˜â€ã€â€œæ¹–åŒ—åŒ»è¯å­¦é™¢ææ—è‹±æ‰â€å’Œâ€œåå °å¸‚å¤ªå’ŒåŒ»é™¢åŒ»å¸ˆèŠ‚ä¼˜ç§€åˆçº§åŒ»å¸ˆâ€ç­‰å¤šç§ç§°å·ã€‚


åœ¨å›½å†…å¤–æœŸåˆŠå‘è¡¨è®ºæ–‡30ä½™ç¯‡ï¼Œè¿‘5å¹´æ¥ä»¥ç¬¬ä¸€ä½œè€…æˆ–é€šè®¯ä½œè€…å‘è¡¨SCIè®ºæ–‡20ç¯‡ï¼Œç´¯è®¡å½±å“å› å­è¿‘100åˆ†ï¼Œ<a href='https://scholar.google.com/citations?user=VnJ0pkYAAAAJ'>google scholar citations <strong><span id=total_cit>400+</span></strong></a> <a href='https://scholar.google.com/citations?user=VnJ0pkYAAAAJ'><img src="https://img.shields.io/endpoint?url={{ url | url_encode }}&logo=Google%20Scholar&labelColor=f6f6f6&color=9cf&style=flat&label=citations"></a>ã€‚


ğŸ”¥ä¸»è¦ç ”ç©¶æ–¹å‘ï¼š
åŸºäºç³–é…µè§£ä»£è°¢é‡ç¼–ç¨‹çš„è‚¿ç˜¤åˆ†å­æ ‡å¿—ç‰©è¯†åˆ«ä¸ç²¾å‡†è¯Šç–—ç­–ç•¥ç ”ç©¶ã€‚

# ğŸ“’ è‡ªç„¶ç§‘å­¦é¡¹ç›®
1. æ¹–åŒ—çœè‚ç™Œç²¾å‡†è¯Šç–—ä¸´åºŠåŒ»å­¦ç ”ç©¶ä¸­å¿ƒï¼Œä¸€èˆ¬é¡¹ç›®ï¼Œ2024LCOF08ï¼ŒRAB3Bä½œä¸ºè‚ç»†èƒç™Œé¢„åç”Ÿç‰©æ ‡å¿—ç‰©é€šè¿‡è°ƒæ§GPIä»‹å¯¼ç³–é…µè§£èƒ½åŠ›å½±å“è‚¿ç˜¤è¿›å±•çš„æœºåˆ¶ç ”ç©¶ï¼Œ2024.01.01è‡³2025.12.31ï¼Œ1.0ä¸‡å…ƒï¼Œåœ¨ç ”ï¼Œä¸»æŒ
2. æ¹–åŒ—åŒ»è¯å­¦é™¢é™„å±å¤ªå’ŒåŒ»é™¢ï¼Œä¸€èˆ¬é¡¹ç›®ï¼Œ2024JJXM087ï¼Œè‚ºè…ºç™Œä¸­ DARS2 çš„è¡¨è¾¾åŠå…¶ä¸è‚¿ç˜¤è¿›å±•çš„æœºåˆ¶ç ”ç©¶ï¼Œ2024-01-01è‡³2025-12-31ï¼Œ0.8ä¸‡å…ƒï¼Œåœ¨ç ”ï¼Œä¸»æŒ
3. æ¹–åŒ—çœæ•™è‚²å…, ä¼˜ç§€ä¸­é’å¹´ç§‘æŠ€åˆ›æ–°å›¢é˜Ÿ, T2020025, åŸºäºHSCsé¶å‘DNAé€‚é…ä½“çš„è‚çº¤ç»´åŒ–è¯Šã€ç–—ä¸€ä½“åŒ–ä½“ç³»å»ºç«‹çš„ç ”ç©¶, 2020-01è‡³2023-12, 20ä¸‡å…ƒ, å·²ç»“é¢˜, å‚åŠ 
4. æ¹–åŒ—åŒ»è¯å­¦é™¢é™„å±å¤ªå’ŒåŒ»é™¢, é™¢çº§é¡¹ç›®, 2023JJXM113, æ¢ç´¢ METTL3 åœ¨é£Ÿç®¡ç™Œç³–é…µè§£ä¸­çš„ä½œç”¨åŠå…¶ä¸ lncRNA SNHG1/miR-101-3p ceRNA ç½‘ç»œçš„ç›¸äº’ä½œç”¨, 2023-01-01è‡³2024-12-31, 0.8ä¸‡å…ƒ, å·²ç»“é¢˜, ä¸»æŒ
5. æ¹–åŒ—åŒ»è¯å­¦é™¢é™„å±å¤ªå’ŒåŒ»é™¢, é™¢çº§é¡¹ç›®, 2022JJXM007, LncRNAKDM7A-DT ä½œä¸º ceRNA è°ƒæ§miR-101-3p é¶å‘ METTL3 å‚ä¸é£Ÿç®¡ç™Œå¢æ®–å’Œç³–é…µè§£çš„æœºåˆ¶åŠåˆ†å­å½±åƒå­¦ç ”ç©¶, 2022-01-01è‡³2023-12-31, 0.8ä¸‡å…ƒ, å·²ç»“é¢˜, ä¸»æŒ
6. æ¹–åŒ—åŒ»è¯å­¦é™¢é™„å±å¤ªå’ŒåŒ»é™¢, é™¢çº§é¡¹ç›®, 2021JJXM006, miR-212-5p é€šè¿‡é¶å‘ m6A ç”²åŸºåŒ–è½¬ç§»é…¶METTL3 æŠ‘åˆ¶é£Ÿç®¡ç™Œç»†èƒå¢æ®–ã€ä¾µè¢­å’Œèƒ½é‡ä»£è°¢çš„æœºåˆ¶ç ”ç©¶, 2021-01-01è‡³2022-12-31, 0.8ä¸‡å…ƒ, å·²ç»“é¢˜, ä¸»æŒ
7. æ¹–åŒ—åŒ»è¯å­¦é™¢, ç ”ç©¶ç”Ÿç§‘æŠ€åˆ›æ–°é¡¹ç›®, YC2019039, è‚ç™Œé¶å‘è½½ä½“scrAAV3ä»‹å¯¼åŸºå› æ²»ç–—å¯è§†åŒ–çš„å®éªŒç ”ç©¶, 2019-03è‡³2020-06, 2ä¸‡å…ƒ, å·²ç»“é¢˜, ä¸»æŒ
8. å›½å®¶è‡ªç„¶ç§‘å­¦åŸºé‡‘å§”å‘˜ä¼š, é’å¹´é¡¹ç›®, 81401447, å¿ƒè‚Œç‰¹å¼‚æ€§å¯åŠ¨å­å¼•å¯¼çš„å¤šæ¨¡æ€æŠ¥å‘ŠåŸºå› æ˜¾åƒæ´»ä½“ç›‘æµ‹å¹²ç»†èƒç§»æ¤æ²»ç–—ç¼ºè¡€æ€§å¿ƒè„ç–¾ç—…çš„æ˜¾åƒç ”ç©¶, 2015-01è‡³2017-12, 23ä¸‡å…ƒ, å·²ç»“é¢˜, å‚åŠ 

# ğŸ“ ä»£è¡¨æ€§æˆæœ 
1. **Liu X S**, Xu Y, Dai L S, et al. The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis[J/OL]. European Journal of Medical Research, 2025, 30(1): 373. DOI:10.1186/s40001-025-02541-3.
2. **Liu X S**, Pei Z J. 18F-FDG PET/CT in the diagnosis and treatment of atypical extensive skin lesions in extranodal natural killer/T-cell lymphoma, nasal type: a case report[J/OL]. Frontiers in Oncology, 2025, 15. DOI:10.3389/fonc.2025.1480661.
3. **Liu X S**, Xie J, Wu R M, et al. Expression patterns of MCM8 in lung adenocarcinoma and its correlation with key biological processes[J/OL]. European Journal of Medical Research, 2025, 30(1): 149. DOI:10.1186/s40001-025-02407-8.
4. Liu Z Y, Yuan L L, Gao Y, Zhang Y, Zhang Y H, Yang Y, Chen Y X, **Liu X S**, Pei Z J. SSB expression is associated with metabolic parameters of 18F-FDG PET/CT in lung adenocarcinoma and can improve diagnostic efficiency[J/OL]. Heliyon, 2024, 10(22): e38702. DOI:10.1016/j.heliyon.2024.e38702.
5. **Liu X S**, Chen Y L, Chen Y X, et al. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers[J/OL]. Scientific Reports, 2024, 14(1): 9881. DOI:10.1038/s41598-024-60581-x.
6. **Liu X S**, Zhang Y, Liu Z Y, et al. METTL3 as a novel diagnosis and treatment biomarker and its association with glycolysis, cuproptosis and ceRNA in oesophageal carcinoma[J/OL]. Journal of Cellular and Molecular Medicine, 2024, 28(6): e18195. DOI:10.1111/jcmm.18195.
7. **Liu X S**, Liu Z Y, Zeng D B, et al. Functional enrichment analysis reveals the involvement of DARS2 in multiple biological pathways and its potential as a therapeutic target in esophageal carcinoma[J/OL]. Aging-us, 2024, 16(4): 3934-3954. DOI:10.18632/aging.205569.
8. **Liu X S**, Chen Y X, Wan H B, et al. TRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association[J/OL]. Scientific Reports, 2024, 14(1): 4042. DOI:10.1038/s41598-024-54670-0.
9. Zhang Y H, **Liu X S**, Gao Y, et al. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters[J/OL]. Lung Cancer, 2024, 188: 107449. DOI:10.1016/j.lungcan.2023.107449.
10. **Liu X S**, Liu C, Chen Y J, et al. Uterine Burkitt Lymphoma with Rare Extranodal Deposits in the Bone, Breast, and Sacral Canal: A Case Report[J/OL]. OncoTargets and Therapy, 2024, 17: 41-44. DOI:10.2147/OTT.S440228.
11. **Liu X S**, Zhang Y, Ming X, et al. SPC25 as a novel therapeutic and prognostic biomarker and its association with glycolysis, ferroptosis and ceRNA in lung adenocarcinoma[J/OL]. Aging-us, 2024, 16(1): 779-798. DOI:10.18632/aging.205418.
12. **Liu X S**, Yuan L L, Gao Y, et al. DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma[J/OL]. Journal of Translational Medicine, 2023, 21(1): 574. DOI:10.1186/s12967-023-04454-3.
13. **Liu X S**, Zeng J, Zhang Y H, et al. DARS2 is a prognostic biomarker and correlated with immune infiltrates and cuproptosis in lung adenocarcinoma[J]. American Journal of Cancer Research, 2023, 13(3): 818-834.
14. **Liu X S**, Liu C, Zeng J, et al. Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis[J/OL]. Frontiers in Pharmacology, 2022, 13: 1010879. DOI:10.3389/fphar.2022.1010879.
15. **Liu X S**, Yang J W, Zeng J, et al. SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA[J/OL]. Frontiers in Cell and Developmental Biology, 2022, 10: 853596. DOI:10.3389/fcell.2022.853596.
16. **Liu X S**, Kui X Y, Gao Y, et al. Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma[J/OL]. Frontiers in Genetics, 2022, 13: 835265. DOI:10.3389/fgene.2022.835265.
17. **Liu X S**, Wu R M, Wan H B, et al. Situs Inversus Totalis on 18F-FDG PET/CT: A Case Report and a Literature Review[J/OL]. Frontiers in Medicine, 2022, 9: 840795. DOI:10.3389/fmed.2022.840795.
18. **Liu X S**, Liu J M, Chen Y J, et al. Comprehensive Analysis of Hexokinase 2 Immune Infiltrates and m6A Related Genes in Human Esophageal Carcinoma[J/OL]. Frontiers in Cell and Developmental Biology, 2021, 9: 715883. DOI:10.3389/fcell.2021.715883.
19. **Liu X S**, Zhou L M, Yuan L L, et al. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis[J/OL]. Frontiers in Immunology, 2021, 12: 724741. DOI:10.3389/fimmu.2021.724741.
20. **Liu X S**, Gao Y, Wu L B, et al. Comprehensive Analysis of GLUT1 Immune Infiltrates and ceRNA Network in Human Esophageal Carcinoma[J/OL]. Frontiers in Oncology, 2021, 11: 665388. DOI:10.3389/fonc.2021.665388.
21. **Liu X S**, Gao Y, Liu C, et al. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma[J/OL]. Frontiers in Oncology, 2021, 10: 606735. DOI:10.3389/fonc.2020.606735.
22. **Liu X S**, Yuan L L, Gao Y, et al. Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma[J/OL]. Journal of Cancer, 2020, 11(16): 4851-4860. DOI:10.7150/jca.44754.
23. **Liu X**, Huang H, Gao Y, et al. Visualization of gene therapy with a liver cancer-targeted adeno-associated virus 3 vector[J/OL]. Journal of Cancer, 2020, 11(8): 2192-2200. DOI:10.7150/jca.39579.

# ğŸ“š æ•™ç ”é¡¹ç›®
1. æ¹–åŒ—åŒ»è¯å­¦é™¢ç ”ç©¶ç”Ÿé™¢ï¼Œæ•™è‚²æ•™å­¦ç ”ç©¶é¡¹ç›®ï¼ŒYJ2025082ï¼ŒåŸºäºOBEç†å¿µçš„BOPPPSæ•™å­¦æ¨¡å¼åœ¨æ ¸åŒ»å­¦ä¸“ä¸šç ”ç©¶ç”Ÿç§‘ç ”èƒ½åŠ›åŸ¹å…»çš„ç ”ç©¶ä¸å®è·µï¼Œ2025.04.10è‡³2027.04.10ï¼Œ0.1ä¸‡å…ƒï¼Œåœ¨ç ”ï¼Œä¸»æŒ
2. æ¹–åŒ—åŒ»è¯å­¦é™¢, æ ¡çº§é¡¹ç›®, YHJ2024011, åŸºäºOBEç†å¿µçš„æ ¸åŒ»å­¦ä¸“ä¸šå‹ç¡•å£«ç ”ç©¶ç”Ÿæ•™è‚²è´¨é‡è¯„ä»·ä½“ç³»æ„å»ºä¸å®è·µ, 2024-01-01è‡³2025-12-31, 0.8ä¸‡å…ƒ, åœ¨ç ”, ä¸»æŒ

# ğŸ“„ ä¸“åˆ©
1. é«˜ç‡•, è£´ä¹‹ä¿Š, åˆ˜æ—­æ˜‡. ä¸€ç§18F-FDG PET/CTä»£è°¢å‚æ•°åœ¨æ„å»ºç›¸åº”è‚¿ç˜¤é¢„æµ‹ç³»ç»Ÿæ–¹é¢çš„åº”ç”¨: ZL202210482438.2[P]. 2025-04-08. å·²æˆæƒ

# ğŸ– ç«èµ›è·å¥–
1. 2024å¹´ç¬¬åå…­å±Šä¸­å—å…­çœï¼ˆåŒºï¼‰æ ¸åŒ»å­¦å­¦æœ¯äº¤æµä¼šã€Šæ ¸åŒ»å­¦åˆ†å­å½±åƒåŒ»å¸ˆé˜…ç‰‡ç«èµ›ã€‹ä¸‰ç­‰å¥–
2. 2023å¹´â€œè¥„åéšç¥â€åŸå¸‚ç¾¤ç¬¬äºŒå±Šè‡ªç„¶ç§‘å­¦ä¼˜ç§€å­¦æœ¯è®ºæ–‡æˆæœå·²å‘è¡¨ç±»ä¸‰ç­‰å¥–
3. 2023å¹´â€œè¥„åéšç¥â€åŸå¸‚ç¾¤ç¬¬äºŒå±Šè‡ªç„¶ç§‘å­¦ä¼˜ç§€å­¦æœ¯è®ºæ–‡æˆæœå·²å‘è¡¨ç±»äºŒç­‰å¥–
4. 2023å¹´â€œæ ¸åŒ»å¥½åŒ»â€PET/CTå…¨å›½ç—…ä¾‹å¤§èµ›(ä¸­éƒ¨èµ›åŒº)æ¢ç´¢ä¹‹æ˜Ÿå¥–
5. 2022å¹´â€œè¥„åéšç¥â€åŸå¸‚ç¾¤é¦–å±Šè‡ªç„¶ç§‘å­¦ä¼˜ç§€å­¦æœ¯è®ºæ–‡æˆæœå·²å‘è¡¨ç±»ä¸‰ç­‰å¥–

# ğŸ‘‘ ä¸ªäººè£èª‰
1. 2022å¹´åå °å¸‚å¤ªå’ŒåŒ»é™¢åŒ»å¸ˆèŠ‚â€œä¼˜ç§€åˆçº§åŒ»å¸ˆâ€
2. 2020å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢2019å¹´åº¦â€œåä½³é’å¹´â€
3. 2020å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢2019å¹´åº¦â€œææ—è‹±æ‰â€
4. 2020å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢ç ”ç©¶ç”Ÿé™¢2020å±Šâ€œä¼˜ç§€æ¯•ä¸šç”Ÿæ ‡å…µâ€
5. 2016å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢è¯æŠ¤å­¦é™¢2016å±Šâ€œä¼˜ç§€æ¯•ä¸šç”Ÿâ€
6. 2015å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢2015å¹´åº¦ä¼˜ç§€å…±äº§å…šå‘˜
7. 2014å¹´æ¹–åŒ—åŒ»è¯å­¦é™¢2014å¹´åº¦ä¼˜ç§€å…±äº§å…šå‘˜
8. 2013å¹´æ¹–åŒ—çœå¤§ä¸­ä¸“å­¦ç”Ÿå¿—æ„¿è€…æš‘æœŸâ€œä¸‰ä¸‹ä¹¡â€ç¤¾ä¼šå®è·µæ´»åŠ¨â€œå…ˆè¿›ä¸ªäººâ€
9. 2013å¹´åå °å¸‚â€œä¼˜ç§€å…±é’å›¢å¹²éƒ¨â€

# ğŸ‘¨â€ğŸ“ å­¦æœ¯ä»»èŒ
1. 2025å¹´Medicine Advancesæ‚å¿—é’å¹´ç¼–å§”
2. 2023å¹´Cancer Advancesæ‚å¿—é’å¹´ç¼–å§”

# ğŸ“– æ•™è‚²ç»å†
- æ¹–åŒ—åŒ»è¯å­¦é™¢ï¼›ç¡•å£«ï¼›2017.09-2020.06
- æ¹–åŒ—åŒ»è¯å­¦é™¢è¯æŠ¤å­¦é™¢ï¼›æœ¬ç§‘ï¼›2012.09-2016.06 



